Posted by Michael Wonder on 27 Aug 2025
Zemcelpro (UM171 cell therapy) receives EC authorisation as the first and only cell therapy for blood cancer patients without access to suitable donor cells
27 August 2025 - ExCellThera announced today the conditional marketing authorisation of Zemcelpro by the European Commission for the treatment of adults with haematological malignancies requiring an allogeneic haematopoietic stem cell transplantation following myeloablative conditioning for whom no other type of suitable donor cells is available.
This decision authorises the marketing of Zemcelpro in all European Union member states, as well as Iceland, Norway and Liechtenstein.
